Research Opportunities

New Research Opportunities


Germany Cancer Research
A German research institution is in need of a healthy in a research opportunity with a global company. The company needed a US-based donor for the next phase of its research development of a cancer drug to treat solid tumors. Study participants will donate mononuclear cells through apheresis, specifically extracting white blood cells.

Blood Centers of America (BCA) recommended Bio-Linked™ to the research firm. The chosen donor will go to Germany for seven days and receive a $500 stipend for the donation.

Aging-Associated Disease Research
A Miami researcher is seeking bone marrow collected in Oklahoma City area for their efforts to help explore research to stop or slow aging-associated diseases. Study participants are asked to spend a few hours at an outpatient facility and donate bone marrow. If you are interested, please make sure you make the following selections in your profile:

PREFERENCES > ARE YOU CURRENTLY AVAILABLE FOR NEW RESEARCH OPPORTUNITIES? Select - YES

PREFERENCES > SELECT AT LEAST ONE DONATION TYPE YOU ARE WILLING TO OFFER. Select - DONATE BONE MARROW

HPV-Associated Cancer Research
A Singapore researcher is seeking whole blood collections to explore cures and treatments for cancers resulting in previous infections of HPV. Study participants are asked to provide their HPV positive test results upon collection of their whole blood. If you are interested in participating in this study, please make sure to select the following selections in your profile:

PREFERENCES > ARE YOU CURRENTLY AVAILABLE FOR NEW RESEARCH OPPORTUNITIES? Select - YES

MY HEALTH HISTORY > WHAT SCREENINGS WERE REPORTED AS POSITIVE? Select - HUMAN PAPILLOMAVIRUS - HPV

Transplant Drug Study
A California immunotherapy research company is seeking white blood cells from adults who weigh at least 110 pounds. Study participants are eligible for compensation up to $1,000 for spending a few hours to donate apheresis white blood cells. If you are interested, please make sure you make the following selections in your profile:

PREFERENCES > ARE YOU CURRENTLY AVAILABLE FOR NEW RESEARCH OPPORTUNITIES? Select - YES

PREFERENCES > SELECT AT LEAST ONE DONATION TYPE YOU ARE WILLING TO OFFER. Select - DONATE APHERESIS WHITE BLOOD CELLS


Oklahoma Research


Type 2 Diabetes Mellitus
The aim of the study is to investigate the long-term impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with T2DM and to compare outcomes against placebo, on a background of standard of care.



Alzheimer's
This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of MK-8931 compared with placebo administered for 78 weeks in the treatment of Alzheimer's Disease (AD). The primary study hypotheses for Part I are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score. The first approximately 400 participants entering Part I of the study are identified as the Safety Cohort. Participants who complete Part I of the study may choose to participate in Part II, which is a long term double-blind extension to assess efficacy and safety of MK-8931 administered for up to an additional 260 weeks.